Hospital
Bergen County Improvement Authority
Bergen County Improvement Authority was paid $37.44M by Medicaid between Jan 2018 and Dec 2024, across 197 billing codes. Its largest line is H0035, Mental health partial hospitalization, treatment, less than 24 hours — 16% of everything it billed.
33Billing provider infoBERGEN COUNTY IMPROVEMENT AUTHORITY
PARAMUS, NJ 07652
PARAMUS, NJ 07652
33aNPI1689682999assigned 08/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.44M
24GClaims679,837
24DCodes billed197
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#42 of 93
Median peer was paid$30.60M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,034 | $6.01M | |
| 2019 | 87,465 | $5.50M | |
| 2020 | 67,462 | $3.78M | |
| 2021 | 110,811 | $4.66M | |
| 2022 | 109,967 | $5.01M | |
| 2023 | 102,315 | $5.94M | |
| 2024incomplete | 82,783 | $6.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 16% | 35,542 | 3,356 | $5.87M |
| G0378 | Hospital observation service, per hour | 7.6% | 3,987 | 2,859 | $2.84M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.3% | 47,567 | 37,757 | $2.72M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 7.0% | 16,362 | 7,959 | $2.60M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 5.9% | 21,159 | 5,899 | $2.21M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 5.8% | 28,548 | 4,680 | $2.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.0% | 8,099 | 7,170 | $1.85M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.8% | 6,869 | 5,847 | $1.79M |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 4.5% | 24,237 | 17,418 | $1.67M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 3.3% | 9,486 | 8,327 | $1.24M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.9% | 29,400 | 12,748 | $1.08M |
| OP259 | 2.8% | 11,667 | 8,851 | $1.06M |
185 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.3% | 18,454 | $871K |
| 80320 | 2.2% | 46,258 | $815K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 13,615 | $717K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 9,294 | $504K |
| 90792 | Psychiatric diagnostic evaluation with medical services | 1.3% | 10,512 | $471K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 14,873 | $451K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 11,486 | $424K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.0% | 7,588 | $387K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 798 | $365K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,741 | $348K |
| 80306 | <1% | 18,519 | $313K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,668 | $263K |
| 36415 | Collection of venous blood by venipuncture | <1% | 52,267 | $252K |
| 80053 | Comprehensive metabolic panel | <1% | 22,740 | $251K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,763 | $215K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,542 | $215K |
| 99205 | Prolong outpt/office vis | <1% | 1,312 | $193K |
| OP272 | <1% | 1,746 | $185K | |
| G0434 | Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter | <1% | 9,959 | $169K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,979 | $169K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,833 | $153K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,699 | $143K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,947 | $114K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 821 | $111K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,120 | $106K |
| 99285 | Emergency room visit (most serious) | <1% | 327 | $103K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,051 | $99K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,076 | $88K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 210 | $77K |
| 80061 | Lipid panel | <1% | 6,118 | $72K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,127 | $61K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,218 | $60K |
| OP370 | <1% | 2,612 | $60K | |
| 80349 | <1% | 2,123 | $54K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,775 | $51K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,646 | $50K |
| 97802 | <1% | 332 | $49K | |
| 84439 | <1% | 5,345 | $46K | |
| 97803 | <1% | 631 | $45K | |
| 81025 | <1% | 4,403 | $42K | |
| 43235 | <1% | 79 | $42K | |
| OP279 | <1% | 2,801 | $41K | |
| 83735 | <1% | 8,318 | $40K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,802 | $40K |
| 82607 | <1% | 3,474 | $40K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,720 | $38K |
| 0012A | <1% | 1,078 | $36K | |
| G0176 | Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more) | <1% | 905 | $33K |
| 85027 | <1% | 4,123 | $32K | |
| 80305 | <1% | 4,789 | $32K | |
| 81001 | <1% | 7,490 | $31K | |
| 90837 | Psychotherapy session, about an hour | <1% | 136 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 568 | $31K |
| OP710 | <1% | 2,735 | $31K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 782 | $30K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,245 | $29K |
| 0011A | <1% | 1,128 | $28K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,804 | $26K |
| 82962 | <1% | 1,821 | $25K | |
| 85610 | <1% | 2,137 | $25K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 261 | $24K |
| Q3014 | Telehealth originating site facility fee | <1% | 1,860 | $22K |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | <1% | 67 | $21K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 315 | $18K |
| G0008 | Administration of influenza virus vaccine | <1% | 658 | $17K |
| 84484 | <1% | 1,205 | $17K | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,375 | $16K |
| 80164 | <1% | 1,930 | $16K | |
| 82550 | <1% | 1,598 | $15K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,615 | $14K |
| 84100 | <1% | 1,327 | $14K | |
| 85007 | <1% | 1,766 | $13K | |
| OP260 | <1% | 135 | $13K | |
| 0064A | <1% | 389 | $13K | |
| 82746 | <1% | 1,053 | $12K | |
| 85730 | <1% | 945 | $12K | |
| 86780 | <1% | 793 | $10K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 155 | $10K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 602 | $10K |
| 80377 | <1% | 208 | $9K | |
| 0004A | <1% | 274 | $8K | |
| 82553 | <1% | 440 | $8K | |
| 86769 | <1% | 279 | $8K | |
| 85048 | <1% | 1,352 | $7K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 126 | $7K |
| OP229 | <1% | 142 | $7K | |
| 83880 | <1% | 304 | $7K | |
| 88342 | <1% | 130 | $7K | |
| 73560 | <1% | 267 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 115 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 103 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 103 | $6K |
| 0001A | <1% | 258 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 46 | $5K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,126 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 354 | $5K |
| 80329 | <1% | 124 | $4K | |
| 72110 | <1% | 94 | $4K | |
| 0002A | <1% | 131 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 103 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 219 | $4K |
| 0124A | <1% | 189 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 55 | $4K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 17 | $3K |
| 83690 | <1% | 667 | $3K | |
| 90674 | <1% | 174 | $3K | |
| 87400 | <1% | 141 | $3K | |
| 0031A | <1% | 83 | $3K | |
| OP258 | <1% | 673 | $3K | |
| 0134A | <1% | 92 | $3K | |
| OP250 | <1% | 117 | $3K | |
| 97161 | <1% | 63 | $3K | |
| 90756 | <1% | 121 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 76 | $3K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 57 | $2K |
| 82570 | <1% | 567 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 49 | $2K |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 1,125 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 744 | $2K |
| 20611 | <1% | 14 | $2K | |
| 86804 | <1% | 145 | $2K | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 361 | $2K |
| 80346 | <1% | 52 | $2K | |
| 90686 | <1% | 99 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 31 | $2K |
| 90732 | <1% | 26 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 160 | $2K |
| 0071A | <1% | 43 | $1K | |
| 82043 | <1% | 403 | $1K | |
| 82150 | <1% | 187 | $1K | |
| 84145 | <1% | 118 | $1K | |
| 0072A | <1% | 35 | $1K | |
| 90661 | <1% | 57 | $1K | |
| 86140 | <1% | 417 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 80 | $1K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 31 | $1K |
| 87077 | <1% | 202 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 235 | $1K |
| 86592 | <1% | 211 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 44 | $989.85 |
| 87340 | <1% | 97 | $953.42 | |
| 83970 | <1% | 15 | $936.28 | |
| 84153 | <1% | 76 | $910.46 | |
| 86706 | <1% | 86 | $907.68 | |
| 73630 | <1% | 36 | $843.74 | |
| 0013A | <1% | 24 | $764.50 | |
| 87186 | <1% | 90 | $742.52 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 588 | $683.81 |
| 73130 | <1% | 17 | $653.62 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 86 | $648.37 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $563.48 |
| 90653 | <1% | 15 | $555.66 | |
| 84550 | <1% | 189 | $553.89 | |
| 92225 | <1% | 15 | $532.68 | |
| 87040 | <1% | 15 | $491.92 | |
| 86704 | <1% | 42 | $478.96 | |
| 81003 | <1% | 354 | $473.42 | |
| 84425 | <1% | 13 | $447.97 | |
| 84146 | <1% | 28 | $432.00 | |
| 88312 | <1% | 32 | $398.48 | |
| 84403 | <1% | 13 | $389.65 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 347 | $305.28 |
| 99242 | <1% | 14 | $300.60 | |
| 85651 | <1% | 114 | $299.86 | |
| 96368 | <1% | 15 | $295.28 | |
| 90480 | <1% | 43 | $256.52 | |
| 91320 | <1% | 13 | $232.66 | |
| 82947 | <1% | 45 | $190.96 | |
| 83550 | <1% | 34 | $169.73 | |
| OP771 | <1% | 35 | $145.35 | |
| 83540 | <1% | 37 | $132.64 | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 32 | $132.30 |
| 84315 | <1% | 43 | $118.32 | |
| 80178 | <1% | 13 | $115.38 | |
| 82270 | <1% | 24 | $43.58 | |
| 82140 | <1% | 13 | $28.21 | |
| 91303 | <1% | 29 | $2.00 | |
| 99024 | <1% | 157 | $1.23 | |
| OP999 | <1% | 16 | $0.02 | |
| 91321 | 0% | 15 | $0.00 | |
| 90611 | 0% | 169 | $0.00 | |
| OP636 | 0% | 23 | $0.00 | |
| 97014 | 0% | 30 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 24 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAGUSEO, MAURO (EXECUTIVE DIRECTOR OF BCIA)
| Provider | Location | Paid |
|---|---|---|
| Bergen County Improvement Authority | Paramus, NJ | $14.50M |
| Bergen County Improvement Authority | Paramus, NJ | $4.37M |
| Bergen County Improvement Authority | Paramus, NJ | $126K |
| Bergen County Improvement Authority | Paramus, NJ | $10K |
| Bergen County Improvement Authority | Paramus, NJ | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.